Small-Cap Stocks: Influential Factors and Prospective Triggers (ZVSA, ASST, INDP, SXTP, FBIO)
Analyzing a selection of five distinct penny stocks for the week demands a focus on potential driving forces in the near future, acknowledging breakout and resistance levels. Proactively foreseeing upward movements and pinpointing crucial entry points are crucial tactics. Practice patience to mitigate risks linked to exploring possible market lows and await confirmation via significant breakout thresholds.
ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA) - ZyVersa Therapeutics, Inc. stock fell 7% last week, closing at $.55. In a recent press release, the company outlined its 2024 outlook, confirming plans to start Phase 2a clinical trials for VAR 200 in diabetic kidney disease patients in Q1 2024. The open-label trial aims for real-time data reads, with initial results expected by mid-year. Diabetic kidney disease is a critical unmet need, being the primary cause of end-stage kidney disease. We'll monitor for company updates and watch for a resistance break at $.59-$.60.
Asset Entities Inc. (NASDAQ: ASST) - Asset Entities Inc. stock dipped by 1% to $.37 in last week's session. The company revealed Ternary V2, the latest version of its Stripe-verified digital community payment processing platform, set to launch in early 2024. Ternary V2 will offer advanced CRM tools for community owners to scale, manage, and process payments in one platform. We'll monitor the $.30 support or look for a resistance break in the $.39-$.40 range and keep an eye out for any company developments.
Indaptus Therapeutics, Inc. (NASDAQ: INDP) - Indaptus Therapeutics, Inc. ended last week's trading at $1.80, marking a 3% increase. In early November, the company shared a positive update on the INDP-D101 trial for Decoy20 in solid tumor treatment. The first cohort showed stable disease and immune activation, with manageable adverse events. The second cohort has commenced with a dose adjustment for a similar response. Completion is expected by early 2024, guiding the recommended Phase 2 dose for future studies in 2024. Jeffrey Meckler, CEO of Indaptus, expressed optimism about the ongoing progress. We'll monitor the resistance break at $1.95 or watch for consolidation around $1.70 and stay alert for upcoming company updates.
60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) - 60 Degrees Pharmaceuticals Inc. stock closed the week 14% lower at $.62. In late December, the company announced IRB-approved Phase IIA clinical study for ARAKODA® regimen in treating hospitalized babesiosis patients. Additionally, the FDA rescheduled the Type C meeting to January 17, 2024, maintaining the agenda. We'll await updates from the January 17th Type C meeting and monitor for a resistance break at $.70.
Fortress Biotech, Inc. (NASDAQ: FBIO) - Fortress Biotech, Inc. stock climbed 3% to $1.90 last week. In the recent November press release, the company showcased Q3 accomplishments, with Chairman Lindsay A. Rosenwald highlighting a total net revenue of $34.8 million. Key upcoming milestones involve potential FDA submissions, including one for DFD-29 to treat rosacea by year-end. Also, the PDUFA goal date for cosibelimab, an investigational anti-PD-L1 antibody, is expected on January 3, 2024. We'll monitor for upcoming company updates and keep a close watch on the resistance zone between $1.95-$2.00.
Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTime Penny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.